The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, which is in a pair of late-stage studies in lupus.
Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12, 2025 ...
The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...
Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...
Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...
Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...
Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech’s litifilimab.
Researchers at Linköping University in Sweden made an unexpected discovery while investigating genetically unique women.
Distractify on MSN23h
Why Does Seal Have Scars? Details on What Happened to His Face and HairWhy does Seal have scars? The singer's facial scars and bumps are caused by a skin condition. Learn what happened to his face ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback